Ramelteon
DrugRamelteon 8 mg tablet by mouth x 1 dose
Other names: Rozerem
NCT Number: NCT00595075
Night shift-workers are often advised to take a prophylactic nap prior to starting the shift in order to improve alertness and performance. However, individuals often report difficulty initiating and maintaining sleep at that time of the day secondary to the alerting influence of the near-24 hour circadian rhythm (biological clock). A sleep-promoting medication may improve the quality of an evening nap and subsequent alertness and performance during a night shift. We will use Ramelteon, a melatonin agonist that is FDA approved for insomnia, in order to test the following hypotheses:
1. ramelteon, compared with placebo, will significantly increase sleep efficiency during a 2-hour nap; 2. sleep inertia, as assessed by neurobehavioral tests and subjective and objective sleepiness assessments will not be significantly increased after ramelteon treatment compared with placebo treatment; and 3. neurobehavioral performance, subjective and objective sleepiness, and subjective mood during a simulated 8-hour night shift will be significantly improved when ramelteon is given prior to a prophylactic nap compared to a prophylactic nap with placebo.
Looking for future studies?
Notify Me18 year–35 year
All sexes
Interventional
Not applicable
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Ramelteon 8 mg tablet by mouth x 1 dose
Other names: Rozerem
placebo identical in appearance to active experimental drug x 1 dose
Time frame: 2 hours
total sleep time/time in bed * 100% (higher values indicate better outcome)
Time frame: 71 minutes
numerical scale of increasing alertness from 0-100 (higher values are better outcome)
Time frame: 71 minutes
numerical scale of increasing sleepiness from 1-9 (higher values indicate worse outcome)
Time frame: 71 minutes
A cognitive throughput task consisting of matching symbols to numerical keys; higher numbers indicate a better score
Time frame: 71 minutes
EEG spectral analysis of 5.5-9.0 Hz frequency activity (theta low-frequency alpha), with higher activity indicating increased drowsiness and worse outcome
Time frame: 8 hours
Visual-motor reaction time in which participants hit a button on a response box as fast as possible in response to a visual target (lower values indicate better outcome)
Time frame: 8 hours
Number of trials per test battery with a reaction time >0.5 seconds (higher values indicate worse outcome)
Brigham and Women's Hospital
Other
Effects of Ramelteon on Sleep and Neurobehavioral Performance in a Simulated Night Shift Preceded by a Sleep Opportunity
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT06702423
Healthy
London, United Kingdom
View Trial DetailsNCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details